Release date: 2014-12-03 Recently, a news of "cultivating bones with stem cells and reducing 900,000 operations a year" was heard in the biomedical world. It is EpiBone, a revolutionary company that uses stem cells and a special type of petri dish to grow durable living bones, allowing patients to “build their own bones†and use them for their own use. Doesn't it sound incredible, mother no longer has to worry about the bears being broken, what is the experimental principle of this biotechnology? The lower arterial network has a detailed combing of EpiBone to see how it rebuilds the bone. Stem cell regeneration bone reconstruction In the United States, approximately 900,000 people undergo bone-related surgery each year, and the procedure is lengthy and painful. EpiBone founder Nina Tandon wants to change this situation: slow down pain, reduce the risk of rejection, and shorten the recovery time. Therefore, regenerated bone was invented. In the EpiBone team's regenerative bone description, the formation of regenerative bone requires three crucial steps: CT scan of the bone injury site; extraction of the patient's own stem cells; stem cell culture. 1) CT scan of the site of the bone defect to obtain its exact size and shape, so that the reconstructed bone can be properly placed in the proper position; 2) Extract stem cells from the patient's bone marrow through a simple procedure similar to liposuction, because stem cells are a type of self-renewing pluripotent cell that can differentiate into multiple species under certain conditions. Functional cells that regenerate specific tissue structures, such as bones. And since the stem cells are taken from the patient itself, the regenerated bone is almost free of body rejection compared to the foreign bone. 3) Put the stem cells taken from the patient in a special culture dish or bioreactor, and provide all the nutrients needed to regenerate the bone. If the nutrition is not right, it is not the regenerated bone needed. It will only follow along. Specific structures are grown to automate bone regeneration. Thereby shortening the recovery time of the surgery. In addition to EpiBone, the arterial network also found a case study similar to bone regeneration: CellTransplant, a researcher at the University of Michigan School of Dentistry and the Michigan Oral Health Research Center, and Aastrom Biosciences, conducted a clinical trial of tibia reconstruction. The cells used for tissue repair cell therapy are bone marrow obtained from the patient's hip. As extracted, the bone marrow is treated to allow many different cells, including stem cells, to grow, which are then implanted in different areas of the mouth and tibia. Nat. Med., a research team led by the University of California, Davis, developed a new technology that uses a molecule to enhance bone growth: when the molecule is injected into the bloodstream, it directs the body's stem cells to run into the bone. Surface, once this molecule directs stem cells to reach the bone surface, these stem cells differentiate into osteoblasts and synthesize proteins that promote bone growth. Development challenge The road ahead of EpiBone will be very challenging, because so far, only a small amount of bones grown in the laboratory have been tested in animals, and human testing has not been done before. Regenerated bone has long-term effects on the human body. Comprehensive research has yet to be completed; another is that the study is relatively simple, compared with the effects of traditional surgery can not be compared frequently, and the patient can not carry out a systematic long-term communication; again, the cost problem, every time a bone transplant is performed It takes an expensive price. Founding team The EpiBone team has five founders: Nina Tandon, CEO of EpiBone, holds a Ph.D., holds an MBA, is a postdoctoral fellow at the Columbia University Stem Cell and Tissue Engineering Laboratory, completed his Ph.D. in 2009, and completed his Executive MBA in 2012. A degree, and a postdoctoral fellow in the healthcare profession, she is a senior researcher at TED, an associate professor in electrical engineering at the Massachusetts Institute of Technology, McKinsey and the Cooper Union College. She has 8 years of experience in bioreactor design and has written about The work of super cells: Architecture and Biology (2014), 14 journal articles, 6 chapters, 3 patents, was named the 2012 Top 100 Most Creative Business Wizard by FC Magazine. Sarindr ICK bhumiratana, Chief Scientific Officer of EpiBone, holds a Ph.D., and is a postdoctoral researcher at the Stem Cell and Tissue Engineering Laboratory at Columbia University. His research interests include: Controlling the assembly of human stem cell tissue matrix through advanced biomaterials and biological responses. The system is transplanted to natural bone and cartilage. He has co-authored 15 journal articles, 3 chapters, and 1 patent invention. Gordana vunjak-novakovic, EpiBone's Chief Scientific Adviser, Professor, Ph.D., Gordana is a visiting professor of biomedical engineering and medical science at Columbia University. At Columbia University, she runs a stem cell and tissue engineering laboratory and is involved. He led the stem cell center of Columbia University, the core experiment of stem cell imaging, the Tissue Engineering Research Center of the National Institutes of Health, and the craniofacial regeneration center. Her research focuses on human tissue regenerative medicine, stem cell research, and disease models. She has published research topics, has more than 70 patents registered, issued, and pending, and is a common consultant to the government and industry. Apart from EpiBone, she is another A partner of a biotechnology company. Often involved in multiple associations, the American Institute of Medical and Bioengineering, the Biomedical Engineering Society, the Hall of Fame Women's International Science and Technology Museum, a founding member of the Tissue Engineering and Regenerative Medicine Research Association, and the first Columbia University female to be elected to the National Academy of Engineering. . Sidney Eisig, EpiBone's Chief Clinical Consultant, Columbia University Professor, Dr. Eisig, oversees and implements all major animal clinical implant dates. He is an oral and maxillofacial surgeon with a strong clinical approach to craniofacial reconstruction. interest of. Since completing an internship in oral and maxillofacial surgery in 1986, his main interest has focused on facial reconstruction of congenital and acquired deformities in children. From 1986 to 2001, he was an oral and maxillofacial surgeon at the Montefiore Medical Center in Bronx, New York, and the craniofacial team at Albert Einstein College of Medicine. He is currently the chair of the Department of Dentistry at Columbia University School of Stomatology. . Dr. Eisig is also the Chief Director of Columbia University Medical Center and the Morgan Stanley Children's Hospital of the New York Presbyterian Church. Elisa Cimetta, a partner at EpiBone, received his Ph.D. in chemical engineering from the University of Padua in Italy in 2009. His research focuses on the design and development of microscale technologies and microfluidic platforms for in vitro stem cell culture, and then served as a human body for one year. A postdoctoral researcher who designs and develops advanced cell culture techniques for tissue production, and then was employed by Columbia University from 2010 to 2013 as an associate researcher to further study the development of advanced technologies for stem cell differentiation in space and time-regulated environments, During the same period, Elisa was a researcher at the New York Stem Cell Foundation. Financing In mid-June this year, EpiBone received $350,000 in research funding from Breakout Labs, a biotechnology investment company founded by Peter Thiel, to promote stem cell therapy for bone growth. In the same period, two companies, Cortexyme and G-Tech Pharmaceuticals, were selected by Breakout to support their early research on Alzheimer's disease and gastrointestinal diseases. Source: Arterial Network
Small breast sex doll and flat breast sex doll is most popular in the market.
Those who like A Cup, B Cup, C Cup, will find their favorite sex dolls here, they will meet all your requirements and sexual fantasies.
Perfect simulated technology:
The internal structure of vagina is completely carried on according to the reality, with a g-spot, countless fold and protuberance.There is a spikes of uterus in the tail ,increased stimulus, real sex appeal.
Vagina structure: The vagina is arising from the mud draft made by the master with 40 years of experience engaged in the wax statue carving,so it is very realistic.
flat chest sex doll,sex doll flat chest,life size flat breast sex ,mini love sex doll,small cup Silicone Sex Doll,cute little girl sex doll.
Real Silicone Doll,Small Breasts Sex Dolls,Realistic Small Breasts Sex Dolls Dongguan Chenkuang Biological Technology Co., Ltd , https://www.cksexdoll.com
